BridgeMD
New treatment option for Sepsis - to Reduce Mortality in the Intensive Care Unit
Official title Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
ClinicalTrials.gov ID: NCT06766461
What this study is testing
What is Double dosing of beta-lactam antibiotic?
Double dosing of beta-lactam antibiotic is an investigational medicine, being studied as a potential treatment for sepsis - to reduce mortality in the intensive care unit.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ≥18 years of age
- Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)
- Primary infection
- Admitted to the ICU
- Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock requiring the start of vasopressors to maintain a mean arterial pressure...
You likely can't join if
- Patient or legal representative not available to give informed consent within 72 hours after admittance
- Pregnancy
- Admittance for burn wounds
- Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)
- Enrolment in another treatment trial
- Patient received the study antibiotic for more than 24 hours before inclusion
See the full eligibility criteria
- ≥18 years of age
- Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)
- Primary infection
- Admitted to the ICU
- Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock requiring the start of vasopressors to maintain a mean arterial pressure 65 mmHg or greater, and a serum lac tate level greater than 2.0 mmol/L...
- Patient or legal representative not available to give informed consent within 72 hours after admittance
- Pregnancy
- Admittance for burn wounds
- Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)
- Enrolment in another treatment trial
- Patient received the study antibiotic for more than 24 hours before inclusion
- Patient receiving extracorporeal membrane oxygenation (ECMO)
- Patient is already treated with a double dose of antibiotics based on suspected infection
The study team makes the final eligibility decision.
Where it's taking place
- Rotterdam, Netherlands
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rotterdam, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.